Symbiotec Pharmalab plans IPO to boost specialty pharma market
Mumbai:
Symbiotec Pharmalab
, a global leader in manufacturing corticosteroid and hormone active pharmaceutical ingredients (APIs), is planning an initial public offering (IPO) in the next 12 months at a targeted valuation of about $1 billion, said people familiar with the matter.
The Indore-based company has appointed Nomura,
JM Financial
, and
Motilal Oswal
as lead managers for the proposed IPO, which aims to raise ₹2,000-2,500 crore, and give a partial exit to existing private equity investors, the people said.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Play War Thunder now for free
War Thunder
Play Now
Undo
Motilal Oswal Private Equity (MOPE) and healthcare-focused PE firm InvAscent collectively hold about 72% stake in Symbiotec. MOPE, via its India Excellence Fund-III, owns 29%, and InvAscent, through Rosewood Investments, holds 42.67% as of March 31, 2024. The remaining 28% stake is held by the promoter Satwani family.
The planned public issue underscores rising interest in
speciality pharma
firms. In 2023, another API-focused firm,
Concord Biotech
, raised ₹1,551 crore through an IPO. Backed by late investor Rakesh Jhunjhunwala, Concord currently has a market capitalisation of ₹18,528 crore, with its stock closing at ₹1,780.75 apiece on the BSE on Tuesday-well above its issue price of ₹741.
Founded in 2002 by Anil Satwani, Symbiotec specialises in research, development, and manufacturing of corticosteroids and hormone APIs at facilities in Rau and Pithampur SEZ, Madhya Pradesh. The company is one of the largest independent firms in its category globally and has built a robust backward-integrated platform for steroid and hormone manufacturing.
Live Events
Symbiotec has also ventured into formulations, currently developing a portfolio of injectable products through its unit, Knovea Pharmaceuticals, which is setting up a dedicated factory in Madhya Pradesh to cater to regulated markets. Another group unit, Symbiotec Zenfold is building a fermentation facility for green nutraceuticals and pharmaceutical precursors.
In FY25, Symbiotec reported a revenue of ₹800 crore and EBITDA of ₹250 crore, people said. During FY24, steroid APIs contributed 68% of revenue with hormones comprising the remainder. The company exports to more than 30 countries, including the US, Europe, and key Asian markets.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
21 minutes ago
- Time of India
Ellenbarrie Industrial Gases IPO GMP rises to 6%; issue subscribed 9% on Day 2
The initial public offering (IPO) of Ellenbarrie Industrial Gases was subscribed 9% so far on the second day of bidding on Wednesday, up from 8% on Day 1. As of 10:03 am, the IPO had received bids for 12,95,222 shares, or 9% of the total issue size of 1,51,08,983 shares. The retail investor portion was subscribed 15%, while the non-institutional investor (NII) category saw a 9% subscription. The qualified institutional buyer (QIB) segment was yet to be subscribed. In the grey market, Ellenbarrie Industrial Gases shares were trading at a premium of Rs 25–26, up from Rs 7–9 on Day 1. This means the GMP has risen to around 6% from 1.75%. Also Read: These 10 penny stocks under Rs 10 surged 200-570% in last 1 year. Do you own any? IPO details Live Events The public issue includes a fresh equity issuance worth Rs 400 crore along with an offer for sale (OFS) of 1.13 crore shares. Ahead of the launch, the company successfully secured Rs 256 crore from anchor investors. The price band has been set at Rs 380 to Rs 400 per share, with a minimum application size of 37 shares. The shares are proposed to be listed on both the NSE and BSE. The IPO proceeds will be utilised to repay debt amounting to Rs 210 crore, establish a 220 TPD air separation unit at the company's Uluberia-II plant at a cost of Rs 104.5 crore, and meet general corporate requirements. Eastern India Gases Ltd (EIGL) also plans to commission three new plants by FY26, aiming to increase its total installed capacity from 3,861 TPD to 4,551 TPD. Also Read: Jio Financial surges over 50% from March lows: Will the momentum sustain? About Ellenbarrie Industrial Gases Founded over five decades ago, EIGL manufactures and supplies a wide range of industrial gases such as oxygen, nitrogen, argon, and acetylene, along with speciality gases, medical gases, and cryogenic storage systems. It operates nine facilities across East, South, and Central India, servicing industries like steel, pharmaceuticals, defence, healthcare, and railways. The company reported a 26.7% PAT margin in FY25 with net profit of Rs 83.3 crore, EBITDA margin of 35.8%, and return on equity of 16.9%. At the upper end of the price band, the stock is valued at 62.9x FY25 earnings. Also Read: Coforge among 10 high-conviction stock ideas that can rally up to 52% Should you subscribe to the Ellenbarrie Industrial Gases IPO? SBI Securities has rated the IPO as Subscribe, citing EIGL's improving margin profile, strong client base, strategic capacity expansion, and attractive valuation compared to listed peers like Linde India . ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of Economic Times)
Mint
21 minutes ago
- Mint
HDB Financial Services day 1 Live: GMP, subscription status, price, date to review. Apply or not to this HDFC Bank arm?
HDB Financial Services IPO: The initial public offering (IPO) of HDB Financial Services Limited has hit the Indian primary market today. The public issue will remain open until 27 June 2025. The HDFC Bank arm company has declared the HDB Financial Services IPO price band at ₹ 700 to ₹ 740 per equity share. The book build issue is proposed for listing on the BSE and the NSE. The initial public offer aims to raise ₹ 12,500 crore from this public issue, out of which ₹ 2,500 crore is aimed at issuing fresh shares. The rest of ₹ 10,000 crore is reserved for the offer for sale (OFS). According to market observers, company shares are available in the grey market well ahead of the HDB Financial Services IPO subscription opening. They said that one share of HDB Financial Services Limited is available at a premium of ₹ 75 in the grey market today. BNP Paribas, JM Financial, BofA Securities India, Goldman Sachs India, HSBC Securities, IIFL Capital Services, Jefferies India, Morgan Stanley India, Motilal Oswal Investment Advisors, Nomura India, Nuvama Wealth Management, UBS Securities India are the book-running lead managers of the HDB Financial IPO. At the same time, MUFG Intime India Private Limited (Link Intime) is the official registrar for the issue. By 11:06 AM on day 1 of bidding, the public issue had been subscribed 0.10 times. The retail portion of the public issue had been booked 0.10 times, whereas the NII segment had been subscribed 0.14 times. 1] HDB Financial Services IPO GMP: According to market observers, the company's shares are available at a premium of ₹ 75 in today's grey market. 2] HDB Financial Services IPO price: The company has declared the price band for the book-build issue at ₹ 700 to ₹ 740 per equity share. 3] HDB Financial IPOHDB Financial Services IPO date: The public issue has opened today and will remain open until 27 June 2025. 4] HDB Financial Services IPO size: The company aims to raise ₹ 12,500 crore, of which ₹ 10,000 crore is reserved for OFS and the rest, ₹ 2,500 crore, is aimed through fresh shares. Infographic: Courtesy mintgenie 5] HDB Financial Services IPO lot size: A bidder can apply in lots, and one lot of the book build issue comprises 20 company shares. 6] HDB Financial Services IPO allotment date: The most likely date to finalise the share allocation is 30 June 2025. 7] HDB Financial IPO registrar: MUFG Intime India Private Limited (Link Intime) has been appointed the official registrar of the book build issue. 8] HDB Financial Services IPO lead managers: BNP Paribas, JM Financial, BofA Securities India, Goldman Sachs India, HSBC Securities, IIFL Capital Services, Jefferies India, Morgan Stanley India, Motilal Oswal Investment Advisors, Nomura India, Nuvama Wealth Management, UBS Securities India have been appointed lead manager of the public issue. 9] HDB Financial Services IPO listing date: The most likely date for listing shares is 2 July 2025. 10] HDB Financial Services IPO review: KR Choksey Securities has given a 'subscribe' tag to the public issue, saying, "HDB's initial issue is priced at 3.4x TTM P/B (considered equity raise for calculating TTM BV) compared to the peer average of 4.4x TTM P/B. We believe the issue is attractively priced, considering its parentage, peer group ROA average and its growth potential. We assign a "SUBSCRIBE" rating to the initial issue of the HDB Financial Service." Sharekhan has also assigned a 'subscribe' tag to the initial offer, saying, "The company is valued at an FY25 price-to-book ratio of ~3.2x/~3.4x at post-issue capital at the lower price band & upper price band respectively, which is reasonable as compared to its peers considering the growth and return ratio profile. Strong parentage and much smaller size than its core peer (Bajaj Finance) provide a long runway for growth. Additionally, a favourable macro environment will be a tailwind for the sector in the near to medium term. We expect healthy listing gains and remain assertive from a medium to long-term perspective." Apart from these, Kunvarji Finstock, Aditya Birla Money, Bajaj Broking, Canara Bank Securities, Centrum Wealth Management, Nirmal Bang, SBI Capital Securities, etc., have also been assigned a 'subscribe' tag to the HDB Financial Services IPO. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
25 minutes ago
- Economic Times
MCX shares jump 5% to hit all-time high as UBS hikes target price to Rs 10,000
Global brokerage firm UBS has raised its target price on MCX shares to Rs 10,000, up from an earlier target price of Rs 7,000, while maintaining a 'Buy' rating on the same. Following the update, the shares of MCX rallied 5% to their all-time high of Rs 8,620 on the BSE. ADVERTISEMENT The brokerage expects increased volatility in key commodities to support volume expansion on the exchange. UBS also highlighted an improving pace and visibility of new product launches, which could further boost investor sentiment. MCX has seen strong trading volumes since April, with futures' average daily value (ADV) rising around 50% QoQ and options premiums ADV up 30% QoQ. Analysts at UBS expect this strength to persist amid geopolitical uncertainties. New launches—like electricity derivatives, monthly bullion contracts, and upcoming index options—are likely to support near-to-medium-term recently launched electricity derivatives and monthly silver options. Initial analysis by the global brokerage firm suggests electricity derivatives could contribute 3–12% to revenue, with a conservative estimate of 3% in FY28 and room for options are expected to gain traction due to a preference for near-expiry contracts. ADVERTISEMENT For context, after launching monthly gold options in November 2024, premium ADVs rose from Rs 1–2 bn to Rs 4–6 bn, and monthly contracts made up 80–95% of gold premium ADVs. These new launches are expected to support near-to-medium-term reported a sharp jump in Q1 trading volumes, with futures ADV rising ~50% QoQ from the earlier stable range of Rs 270–280 billion, driven primarily by increased activity in gold and silver. ADVERTISEMENT Option premiums' ADV also grew 30% QoQ, reaching Rs 43 billion. Based on these trends, analysts estimate trading revenue growth of 34–35% QoQ and a 50% increase in PAT, aided by the absorption of seasonal Q4 expenses like higher staffing and license on these trends, UBS has raised its FY27–FY28 earnings per share (EPS) estimates by 13–17%. MCX is currently trading at around 42x FY27E PE, and analysts believe the market is not yet fully factoring in the exchange's new product growth potential and volume-led margin benefits. ADVERTISEMENT Also read: HDFC Bank unit HDB Financial Services' Rs 12,500 crore IPO opens; GMP at 10%. Should you subscribe? Over the past year, MCX shares have delivered an impressive 117.28% return. The stock is up 36.27% year-to-date (YTD), while gaining 35% over the last six months. In the past three months alone, the stock has surged 66.11%, and in the most recent one-month period, it has risen 31.96%. ADVERTISEMENT Around 10:45 am, the shares of MCX were trading 4.6% higher at Rs 8,591.35 on the BSE. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
